Site Map

While ARESTIN^® has been demonstrated along with SRP to reduce pocket depth and bacteria in patients with periodontal disease, it has not been proven in clinical trials to reduce tooth loss.

INDICATION
ARESTIN^® is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN^® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION
ARESTIN^® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face, and pruritus have been reported with the use of ARESTIN^®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

Please see full Prescribing Information

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

ARESTIN^® is a registered trademark of OraPharma, Inc.

1-866-ARESTIN (1-866-273-7846)

This site is published by OraPharma, Inc., which is solely responsible for its contents. It is intended for visitors from the United States.

Privacy Policy | Legal Notice | Prescribing information | Material Safety Data Sheet | OraPharma, Inc. | Site Map

Manufactured for OraPharma, Inc. © OraPharma, Inc. 2005-2013